SpringWorks' NF1 Plexiform Neurofibroma Trial
Author: SpringWorks Therapeutics
Published On: 01/28/2020
SpringWorks is testing an investigational MEK inhibitor, mirdametinib, in a Phase 2b clinical trial, known as the ReNeu trial. Mirdametinib is under development as an oral, small molecule, selective inhibitor of MEK1 and MEK2, which play key roles in the MAPK signaling pathway—in other words, mirdametinib is designed to target a key pathway in the body that is known to play a role in many types of cancers and rare diseases.
What is the ReNeu trial?
The ReNeu trial is a Phase 2b clinical trial designed to evaluate the safety, effectiveness, and tolerability of an investigational medicine called mirdametinib in children 2 years or older and adults with an inoperable NF1-PN.
The ReNeu trial is an open-label study, meaning that both study participants and doctors are aware of the study treatment being given.
Read more about the ReNeu trial here.
Want to view archived newsletters? Click Here!
Newsletter
Sign up to receive the latest neurofibromatosis news and information in your inbox!
Subscribe